Thrombotic Microangiopathy
7 drugs4,445 FAERS reportsMedDRA PT
GET
/api/v1/reaction/thrombotic-microangiopathyReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D057049
Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.
Source: U.S. National Library of Medicine — MeSH (Thrombotic Microangiopathies)
Drugs reporting Thrombotic Microangiopathy (7)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Narsoplimab321%
- 2Basiliximab3963.4%
- 3Sirolimus3672.8%
- 4Thiotepa2612.8%
- 5Busulfan4842.7%
- 6Belatacept1002.2%
- 7Tacrolimus2,8341.9%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Transplant Rejection4 shared · 0.31
- Cytomegalovirus Infection7 shared · 0.30
- Post Transplant Lymphoproliferative Disorder2 shared · 0.29
- Chronic Graft Versus Host Disease2 shared · 0.22
- Kidney Transplant Rejection2 shared · 0.22
- Acute Graft Versus Host Disease In Skin2 shared · 0.20
- Acute Graft Versus Host Disease2 shared · 0.15
- Graft Versus Host Disease2 shared · 0.14
- Venoocclusive Liver Disease2 shared · 0.13
- Cytomegalovirus Infection Reactivation2 shared · 0.12
Literature
Recent PubMed references pinned to Thrombotic Microangiopathies as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Age-related and disease-specific changes in B-cell profiles in older adults with immune thrombocytopenia.Frontiers in immunology · 2026 · Monzón Manzano E, Herrero Carrasco C, Acuña P, et al.PMID 42206040DOI 10.3389/fimmu.2026.1791460
- Mutation Spectrum of ADAMTS13 Gene in Patients with Upshaw-Schulman Syndrome (USS) in Russia.International journal of molecular sciences · 2026 · Poznyakova J, Pshenichnikova O, Klebanova E, et al.PMID 42196618DOI 10.3390/ijms27104643
- Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.Hematology (Amsterdam, Netherlands) · 2026 · Tan A, Liu J, Chen X, et al.PMID 42179326DOI 10.1080/16078454.2026.2678626
- Dapsone and schistocytes: Thrombotic microangiopathy or not?PloS one · 2026 · Archambeaud A, Aumont C, Pouplard C, et al.PMID 42172240DOI 10.1371/journal.pone.0349570
- Low-density granulocyte-driven NET formation is associated with poor prognosis in IgA nephropathy with thrombotic microangiopathy.Renal failure · 2026 · Li Q, You J, Fan J, et al.PMID 42161885DOI 10.1080/0886022X.2026.2667670
- Severe mesangiolysis with prominent microaneurysm formation following total body irradiation conditioning for bone marrow transplantation.CEN case reports · 2026 · Nakagawa Y, Koizumi M, Shimamura N, et al.PMID 42159831DOI 10.1007/s13730-026-01130-5
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.